Insider Transactions in Q4 2024 at Becton Dickinson & CO (BDX)
Insider Transaction List (Q4 2024)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 19
2024
|
Michael David Garrison EVP & President, Medical |
SELL
Open market or private sale
|
Direct |
2,838
-31.61%
|
$632,874
$223.33 P/Share
|
Dec 09
2024
|
Roland Goette EVP and President, EMEA |
SELL
Open market or private sale
|
Direct |
638
-4.29%
|
$139,722
$219.03 P/Share
|
Dec 06
2024
|
Roland Goette EVP and President, EMEA |
SELL
Sale (or disposition) back to the issuer
|
Direct |
9,490
-38.98%
|
$2,097,290
$221.01 P/Share
|
Dec 06
2024
|
Roland Goette EVP and President, EMEA |
SELL
Open market or private sale
|
Direct |
4,483
-15.55%
|
$990,743
$221.01 P/Share
|
Dec 06
2024
|
Roland Goette EVP and President, EMEA |
BUY
Exercise of conversion of derivative security
|
Direct |
13,334
+20.88%
|
$2,093,438
$157.79 P/Share
|
Dec 06
2024
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Open market or private sale
|
Direct |
1,000
-5.56%
|
$220,000
$220.49 P/Share
|
Dec 05
2024
|
David Shan EVP and Chief ISC Officer |
SELL
Open market or private sale
|
Direct |
1,500
-19.27%
|
$330,000
$220.25 P/Share
|
Nov 26
2024
|
Pavan Kumar Mocherla EVP & President Greater Asia |
SELL
Payment of exercise price or tax liability
|
Direct |
20
-0.7%
|
-
|
Nov 26
2024
|
Pavan Kumar Mocherla EVP & President Greater Asia |
BUY
Grant, award, or other acquisition
|
Direct |
1,055
+15.21%
|
-
|
Nov 26
2024
|
Michelle Quinn EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
376
-5.15%
|
-
|
Nov 26
2024
|
Michelle Quinn EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,348
+13.65%
|
-
|
Nov 26
2024
|
Shana Carol Neal EVP and Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
509
-2.75%
|
-
|
Nov 26
2024
|
Shana Carol Neal EVP and Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,109
+10.23%
|
-
|
Nov 26
2024
|
Michael Feld EVP & President, Life Sciences |
BUY
Grant, award, or other acquisition
|
Direct |
2,553
+21.74%
|
-
|
Nov 26
2024
|
Antoine C Ezell EVP, President Americas & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,357
-10.18%
|
-
|
Nov 26
2024
|
Antoine C Ezell EVP, President Americas & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
4,007
+13.95%
|
-
|
Nov 26
2024
|
Christopher Del Orefice EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,192
-19.45%
|
-
|
Nov 26
2024
|
Christopher Del Orefice EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,899
+23.45%
|
-
|
Nov 26
2024
|
Richard Byrd EVP & President Interventional |
SELL
Payment of exercise price or tax liability
|
Direct |
1,204
-11.41%
|
-
|
Nov 26
2024
|
Richard Byrd EVP & President Interventional |
BUY
Grant, award, or other acquisition
|
Direct |
4,495
+19.44%
|
-
|
Nov 26
2024
|
Thomas E Polen Jr Chairman, CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
23,564
-19.01%
|
-
|
Nov 26
2024
|
Thomas E Polen Jr Chairman, CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
52,124
+18.95%
|
-
|
Nov 26
2024
|
David Shan EVP and Chief ISC Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
124
-1.57%
|
-
|
Nov 26
2024
|
David Shan EVP and Chief ISC Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,216
+13.15%
|
-
|
Nov 26
2024
|
Roland Goette EVP and President, EMEA |
SELL
Payment of exercise price or tax liability
|
Direct |
196
-1.25%
|
-
|
Nov 26
2024
|
Roland Goette EVP and President, EMEA |
BUY
Grant, award, or other acquisition
|
Direct |
3,105
+9.31%
|
-
|
Nov 26
2024
|
Michael David Garrison EVP & President, Medical |
SELL
Payment of exercise price or tax liability
|
Direct |
1,230
-12.05%
|
-
|
Nov 26
2024
|
Michael David Garrison EVP & President, Medical |
BUY
Grant, award, or other acquisition
|
Direct |
4,828
+21.28%
|
-
|